Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 24167296)

1.

Immunosignatures can predict vaccine efficacy.

Legutki JB, Johnston SA.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18614-9. doi: 10.1073/pnas.1309390110. Epub 2013 Oct 28.

2.

Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes.

Tan L, Lu H, Zhang D, Tian M, Hu B, Wang Z, Jin N.

Virol J. 2010 Dec 7;7:363. doi: 10.1186/1743-422X-7-363.

3.

A general method for characterization of humoral immunity induced by a vaccine or infection.

Legutki JB, Magee DM, Stafford P, Johnston SA.

Vaccine. 2010 Jun 17;28(28):4529-37. doi: 10.1016/j.vaccine.2010.04.061. Epub 2010 May 5.

PMID:
20450869
4.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

5.

Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.

Tan PT, Heiny AT, Miotto O, Salmon J, Marques ET, Lemonnier F, August JT.

PLoS One. 2010 Jan 18;5(1):e8754. doi: 10.1371/journal.pone.0008754.

6.

Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine.

Sun Y, Bian C, Xu K, Hu W, Wang T, Cui J, Wu H, Ling Z, Ji Y, Lin G, Tian L, Zhou Y, Li B, Hu G, Yu N, An W, Pan R, Zhou P, Leng Q, Huang Z, Ma X, Sun B.

PLoS One. 2010 Dec 9;5(12):e14270. doi: 10.1371/journal.pone.0014270.

7.

Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.

Staneková Z, Király J, Stropkovská A, Mikušková T, Mucha V, Kostolanský F, Varečková E.

Acta Virol. 2011;55(1):61-7.

PMID:
21434706
8.

Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model.

Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K.

PLoS One. 2011;6(9):e24626. doi: 10.1371/journal.pone.0024626. Epub 2011 Sep 19.

9.

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes.

Levi R, Aboud-Pirak E, Leclerc C, Lowell GH, Arnon R.

Vaccine. 1995 Oct;13(14):1353-9.

PMID:
8585293
10.

[Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].

Huang BY, Wang XP, Wang WL, Hu W, Gao Q, Tan WJ, Ruan L.

Bing Du Xue Bao. 2011 May;27(3):265-73. Chinese.

PMID:
21774253
11.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

12.

Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.

Zhou C, Zhou L, Chen YH.

Vaccine. 2012 May 14;30(23):3463-9. doi: 10.1016/j.vaccine.2012.03.021. Epub 2012 Mar 21.

PMID:
22446634
13.

Evaluation of biological sample preparation for immunosignature-based diagnostics.

Chase BA, Johnston SA, Legutki JB.

Clin Vaccine Immunol. 2012 Mar;19(3):352-8. doi: 10.1128/CVI.05667-11. Epub 2012 Jan 11.

14.

The epitope regions of H1-subtype influenza A, with application to vaccine efficacy.

Deem MW, Pan K.

Protein Eng Des Sel. 2009 Sep;22(9):543-6. doi: 10.1093/protein/gzp027. Epub 2009 Jul 3.

15.

Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.

Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler-Moore JP, Fujii G.

Vaccine. 2006 Jun 12;24(24):5158-68. Epub 2006 May 2.

PMID:
16713037
16.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK.

PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30.

17.

Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice.

Tan L, Lu H, Zhang D, Wang K, Tian M, Liu C, Liu Y, Hu B, Jin N.

Sci China Life Sci. 2011 Apr;54(4):293-9. doi: 10.1007/s11427-011-4150-5. Epub 2011 Mar 17.

PMID:
21416231
18.

A candidate vaccine against influenza virus intensively improved the immunogenicity of a neutralizing epitope.

Lu Y, Ding J, Liu W, Chen YH.

Int Arch Allergy Immunol. 2002 Mar;127(3):245-50.

PMID:
11979050
19.

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Brühl P, Kreil TR, Ehrlich HJ, Barrett PN.

PLoS One. 2010 Feb 23;5(2):e9349. doi: 10.1371/journal.pone.0009349.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk